Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | SHMT2 | P34897 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3182485 | 0.81 | BRD4 (0.44) | ALDH1A1KDM4EMAPTTP53L3MBTL1 | |
| SCHEMBL3173168 | 0.80 | L3MBTL1 (0.53) | ALDH1A1KDM4EMAPTL3MBTL1KMT2A | |
| SCHEMBL3175282 | 0.76 | L3MBTL1 (0.39) | ALDH1A1KDM4EMAPTL3MBTL1KMT2A | |
| SCHEMBL27766865 | 0.72 | ALDH1A1 (0.38) | ALDH1A1KDM4EMAPTL3MBTL1KMT2A | |
| SCHEMBL3175610 | 0.68 | NOTUM (0.46) | ALDH1A1KDM4EMAPTTP53CYP2C9 | |
| SCHEMBL4252487 | 0.67 | ALDH1A1 (0.46) | ALDH1A1MAPTKMT2A | |
| SCHEMBL30910849 | 0.62 | KMT2A (0.42) | ALDH1A1KMT2A | |
| SCHEMBL1928826 | 0.62 | KMT2A (0.42) | ALDH1A1KMT2A | |
| SCHEMBL1476384 | 0.62 | L3MBTL1 (0.57) | ALDH1A1L3MBTL1KMT2A | |
| SCHEMBL3175796 | 0.61 | BRD4 (0.53) | ALDH1A1KDM4EMAPTTP53CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100016376-A1 | CASPASE INHIBITORS BASED ON PYRIDONE SCAFFOLD | LG LIFE SCIENCES LTD. (KR) | 2010-01-21 | — | — | US | disclosed |
| CN-101558041-A | Caspase inhibitors based on pyridone scaffold | LG LIFE SCIENCES LTD (KR) | 2009-10-14 | — | — | CN | disclosed |
| EP-2079698-A1 | CASPASE INHIBITORS BASED ON PYRIDAZINONE SCAFFOLD | LG Life Sciences Ltd. (KR) | 2009-07-22 | — | — | EP | disclosed |
| WO-2008056898-A1 | CASPASE INHIBITORS BASED ON PYRIDAZINONE SCAFFOLD | LG LIFE SCIENCES LTD. (KR) | 2008-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016376-A1 | CASPASE INHIBITORS BASED ON PYRIDONE SCAFFOLD | CASP1, CASP5, CASP2 | ALDH1A1 3290/4885KDM4E 1345/4885HSD17B10 741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.